Effect of fixed-dose losartan/hydrochlorothiazide on brain natriuretic peptide in patients with hypertension

Abstract

Objective: Losartan/hydrochlorothiazide (HCTZ) (Preminent®) is a fixed-dose combination of angiotensin II receptor blocker (ARB) and the thiazide diuretic HCTZ that has consistently been shown to be more effective than either losartan or HCTZ. Little is known about the relationship between losartan/HCTZ and blood levels of brain natriuretic peptide (BNP).

Methods and results: In this study, 44 patients with hypertension who were being treated with ARB were enrolled. The ARB was changed to losartan/HCTZ because of uncontrolled hypertension. Blood pressure (BP), pulse rate (PR), plasma levels of BNP and other biochemical parameters were analyzed at baseline and 6 and 12 months after the change from ARB. Of the total 44 patients, 33 (75%) achieved the target BP at 12 months. While there was no significant change in PR, systolic and diastolic BP were significantly reduced (−23 ± 3 mmHg and −10 ± 2 mmHg, respectively) during this period. Although there were no significant changes in biochemical parameters, plasma levels of BNP were significantly decreased, especially in patients who had higher levels of BNP at baseline, during this period.

Conclusion: Losartan/HCTZ therapy significantly reduced not only BP but also plasma levels of BNP in patients with hypertension. These findings suggest that losartan/HCTZ might have cardioprotective effects in patients with higher levels of BNP.

Keywords

Angiotensin II receptor blocker blood pressure brain natriuretic peptide diuretic losartan/hydrochlorothiazide

Get full access to this article

View all access options for this article.

References

Dahlöf

Sever

Poulter

Wedel

Beevers

Caulfield

. (ASCOT Investigators). Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.

Ogihara

Kikuchi

Matsuoka

Fujita

Higaki

Horiuchi

. (Japanese Society of Hypertension Committee). The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3–107.

Martina

Dieterle

Weinbacher

Battegay

. Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. Cardiology 1999; 92: 110–114.

Vogt

Waanders

Boomsma

de Zeeuw

Navis

. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19: 999–1007.

MacKay

Arcuri

Goldberg

Snapinn

Sweet

. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996; 156: 278–285.

Soffer

Wright

Jr Pratt

Wiens

Goldberg

Sweet

. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112–117.

Dickstein

Cohen-Solal

Filippatos

McMurray

Ponikowski

Poole-Wilson

. (ESC Committee for Practice Guidelines (CPG)). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10: 933–989.

Soualmia

Ayadi

Omar

Feki

Drissa

Mebazaa

. Atrial natriuretic peptide and brain natriuretic peptide release in human essential hypertension. Clin Lab 2009; 55: 120–127.

Burnier

. Angiotensin II type 1 receptor blockers (review). Circulation 2001; 103: 904–912.

10.

Miura

Karnik

Saku

. Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst 2011; 12: 1–7.

11.

Fabia

Abdilla

Oltra

Fernandez

Redon

. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007; 25: 1327–1336.

12.

Kato

Eto

. Diuretics in the LIFE study. Lancet 2004; 364: 413.

13.

Benson

Pershadsingh

Chittiboyina

Desai

Pravenec

. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993–1002.

14.

Derosa

Ragonesi

Mugellini

Ciccarelli

Fogari

. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004; 2: 457–464.

15.

Suzuki

Hamada

Yamamoto

Kazatani

Hiwada

. Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. Hypertens Res 2002; 25: 669–676.

16.

Levin

Gardner

Samson

. Natriuretic peptides. N Engl J Med 1998; 339: 321–328.

17.

Fossum

Olsen

Høieggen

Wachtell

Reims

Kjeldsen

. Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. J Clin Hypertens 2006; 8: 169–173.

18.

van Brummelen

Man in ’t Veld

Schalekamp

. Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders. Clin Pharmacol Ther 1980; 27: 328–336.